Crisdesalazine

Crisdesalazine
Clinical data
Trade names	GedaCure
Other names	AAD-2004; AAD2004
Drug class	Microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor; Free radical scavenger
Identifiers
	IUPAC name 2-hydroxy-5-[2-[4-(trifluoromethyl)phenyl]ethylamino]benzoic acid;
CAS Number	927685-43-6;
PubChem CID	16042343;
DrugBank	DB18405;
ChemSpider	13170885;
UNII	11VWK61J69;
Chemical and physical data
Formula	C16H14F3NO3
Molar mass	325.287 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1CCNC2=CC(=C(C=C2)O)C(=O)O)C(F)(F)F;
	InChI InChI=1S/C16H14F3NO3/c17-16(18,19)11-3-1-10(2-4-11)7-8-20-12-5-6-14(21)13(9-12)15(22)23/h1-6,9,20-21H,7-8H2,(H,22,23); Key:UTMVACIBQLDZLP-UHFFFAOYSA-N;

Crisdesalazine (INNTooltip International Nonproprietary Name; developmental code name AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and free radical scavenger which is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and spinal muscular atrophy. It was also under development for the treatment of arthritis, diabetes, pain, and pancreatitis, but development for these indications was discontinued. Crisdesalazine is also approved under the brand name GedaCure for treatment of dogs with canine cognitive dysfunction.